Skip to content
type1.science
N/A (device / behavioral)Not yet recruitingNCT07322380

Quebec screening program for relatives of people with T1D

What this study tests

Quebec feasibility study of islet-autoantibody screening for first-degree relatives of people with type 1 diabetes, evaluating participant-selected centralized versus decentralized follow-up monitoring after a positive screen.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2026-03-04.

Most recent recorded citation date: 2026-03-04. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Adults aged 18 or older living in Quebec who have a first-degree relative (parent, sibling, or offspring) living with type 1 diabetes, per the registry inclusion criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet; the registry record has no results section and lists the study as not yet recruiting.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: Canada. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Feasibility of screening and monitoring outcomes, measured per the registry as the percentage of eligible participants consenting to participate, through study completion

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]